BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
BlossomHill Therapeutics presented updated Phase 1/2 SOLARA data at the IASLC 2026 World Conference on Lung Cancer showing BH-30643 produced a 45% objective response rate (18/40) and an 88% disease control rate in EGFR C797S-positive NSCLC patients who progressed on prior EGFR inhibitors. Safety across 174 patients at expansion doses was favorable, with treatment-related dose reductions in 9% and discontinuations in only 3%; the most common related adverse event was generally asymptomatic bilirubin elevation consistent with UGT1A1 inhibition.
Key figures
- Drug Name
- BH-30643
- Phase Of Trial
- Phase 1/2
- Dcr
- 88% (35/40)
- Orr
- 45% (18/40)
- Trial
- SOLARA (NCT06706076)
- Orr 95ci
- 29%-62%
- Concurrent t790m
- 35%
- Phase2 initiation
- Q1 2027
- Prior osimertinib
- 98%
- Prior chemo or adc
- 53%
- Median followup months
- 6.9
- Regulatory designation
- FDA Fast Track
- Brain metastases history
- 53%
- Median prior lines of therapy
- 2
- Patients remaining on treatment
- 63% (25/40)
- Treatment related dose reductions
- 9%
- Treatment related discontinuations
- 3%
- Patients treated at expansion doses
- 174
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.